Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.54 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973928 | 0.86 | PARP1 (0.50) | ERN1ARCA1CA2BRD4 | |
| SCHEMBL15962141 | 0.85 | KIF11 (0.55) | ERN1 | |
| SCHEMBL34465392 | 0.77 | MGLL (0.48) | CA1CA2ACLY | |
| SCHEMBL12607544 | 0.77 | ERN1 (0.75) | ERN1MKNK1MKNK2MAP4K4 | |
| SCHEMBL8297932 | 0.76 | MAP4K4 (0.54) | ERN1MKNK1MKNK2MAP4K4CA12 | |
| SCHEMBL29954222 | 0.75 | PARP1 (0.50) | ERN1ARCA1CA2BRD4 | |
| SCHEMBL10195681 | 0.75 | PARP1 (0.50) | ERN1ARCA1CA2BRD4 | |
| SCHEMBL14830590 | 0.74 | ERN1 (0.48) | ERN1MKNK1MKNK2MAP4K4AR | |
| SCHEMBL30958375 | 0.74 | CHEK2 (0.67) | MKNK1MKNK2MAP4K4CHEK2PARP1 | |
| SCHEMBL15547657 | 0.74 | CHEK2 (0.67) | MKNK1MKNK2MAP4K4CHEK2PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630979-B2 | Inhibitors of monoacylglycerol lipase and methods of their use | INFINITY PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. | 2014-08-21 | — | — | US | disclosed |
| WO-2013049332-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| WO-2013049332-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | INFINITY PHARMACEUTICALS, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235580-A1 | INHIBITORS OF MONOACYLGLYCEROL LIPASE AND METHODS OF THEIR USE | MGLL, PNLIP, LIPC | ERN1 1582/4885MKNK1 1098/4885MKNK2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.